Viewing Study NCT04735861


Ignite Creation Date: 2025-12-24 @ 1:10 PM
Ignite Modification Date: 2026-03-14 @ 10:59 PM
Study NCT ID: NCT04735861
Status: COMPLETED
Last Update Posted: 2024-08-13
First Post: 2021-01-29
Is Gene Therapy: True
Has Adverse Events: False

Brief Title: Sintilimab Plus Bevacizumab in Recurrent/Persistent Ovarian Clear Cell Carcinoma
Sponsor: Tongji Hospital
Organization:

Conditions & Keywords Data

Conditions:

Conditions

Condition Brief Condition Text View
None Ovarian Clear Cell Carcinoma View
Keywords:

Keywords

Keyword Brief Keyword Text View
None Ovarian clear cell carcinoma View
None PD-1 inhibitor View
None Antiangiogenic therapy View